190 related articles for article (PubMed ID: 36338744)
1. Multi-spectral immunofluorescence evaluation of the myeloid, T cell, and natural killer cell tumor immune microenvironment in chordoma may guide immunotherapeutic strategies.
Lopez DC; Robbins YL; Kowalczyk JT; Lassoued W; Gulley JL; Miettinen MM; Gallia GL; Allen CT; Hodge JW; London NR
Front Oncol; 2022; 12():1012058. PubMed ID: 36338744
[TBL] [Abstract][Full Text] [Related]
2. Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma.
Huo X; Ma S; Wang C; Song L; Yao B; Zhu S; Li P; Wang L; Wu Z; Wang K
Clin Transl Med; 2023 Oct; 13(10):e1429. PubMed ID: 37784253
[TBL] [Abstract][Full Text] [Related]
3. Chordoma cancer stem cell subpopulation characterization may guide targeted immunotherapy approaches to reduce disease recurrence.
Lopez DC; Fabian KP; Padget MR; Robbins YL; Kowalczyk JT; Lassoued W; Pastor DM; Allen CT; Gallia GL; Gulley JL; Hodge JW; London NR
Front Oncol; 2024; 14():1376622. PubMed ID: 38741774
[TBL] [Abstract][Full Text] [Related]
4. Multimodal profiling of chordoma immunity reveals distinct immune contextures.
van Oost S; Meijer DM; Ijsselsteijn ME; Roelands JP; van den Akker BEMW; van der Breggen R; Briaire-de Bruijn IH; van der Ploeg M; Wijers-Koster PM; Polak SB; Peul WC; van der Wal RJP; de Miranda NFCC; Bovee JVMG
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38272563
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Spatial Organization of Suppressive Myeloid Cells and Effector T Cells in Colorectal Cancer-A Potential Tool for Discovering Prognostic Biomarkers in Clinical Research.
Zwing N; Failmezger H; Ooi CH; Hibar DP; Cañamero M; Gomes B; Gaire F; Korski K
Front Immunol; 2020; 11():550250. PubMed ID: 33193316
[TBL] [Abstract][Full Text] [Related]
6. Combinatorial Natural Killer Cell-based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells.
Hoke ATK; Padget MR; Fabian KP; Nandal A; Gallia GL; Bilusic M; Soon-Shiong P; Hodge JW; London NR
Cancer Res Commun; 2021 Dec; 1(3):127-139. PubMed ID: 35765577
[TBL] [Abstract][Full Text] [Related]
7. Augmentation of tumor expression of HLA-DR, CXCL9, and CXCL10 may improve olfactory neuroblastoma immunotherapeutic responses.
Larkin RM; Lopez DC; Robbins YL; Lassoued W; Canubas K; Warner A; Karim B; Vulikh K; Hodge JW; Floudas CS; Gulley JL; Gallia GL; Allen CT; London NR
J Transl Med; 2024 May; 22(1):524. PubMed ID: 38822345
[TBL] [Abstract][Full Text] [Related]
8. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
Fujii R; Schlom J; Hodge JW
J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
[TBL] [Abstract][Full Text] [Related]
9. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
Gaggero S; Witt K; Carlsten M; Mitra S
Front Immunol; 2020; 11():621225. PubMed ID: 33584718
[TBL] [Abstract][Full Text] [Related]
10. Single-cell transcriptome profiling reveals intra-tumoral heterogeneity in human chordomas.
Duan W; Zhang B; Li X; Chen W; Jia S; Xin Z; Jian Q; Jian F; Chou D; Chen Z
Cancer Immunol Immunother; 2022 Sep; 71(9):2185-2195. PubMed ID: 35084549
[TBL] [Abstract][Full Text] [Related]
11. B7-H3 as a Target for CAR-T Cell Therapy in Skull Base Chordoma.
Long C; Li G; Zhang C; Jiang T; Li Y; Duan X; Zhong G
Front Oncol; 2021; 11():659662. PubMed ID: 34868903
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma.
Morimoto Y; Tamura R; Ohara K; Kosugi K; Oishi Y; Kuranari Y; Yoshida K; Toda M
J Neurooncol; 2019 Aug; 144(1):65-77. PubMed ID: 31240525
[TBL] [Abstract][Full Text] [Related]
13. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
14. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
[TBL] [Abstract][Full Text] [Related]
15. Identification of neuroblastoma cell lines with uncommon TAZ
Canzonetta C; Pelosi A; Di Matteo S; Veneziani I; Tumino N; Vacca P; Munari E; Pezzullo M; Theuer C; De Vito R; Pistoia V; Tomao L; Locatelli F; Moretta L; Caruana I; Azzarone B
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452207
[TBL] [Abstract][Full Text] [Related]
16. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
[TBL] [Abstract][Full Text] [Related]
17. Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment.
Kaweme NM; Zhou F
Front Immunol; 2021; 12():683381. PubMed ID: 34220833
[TBL] [Abstract][Full Text] [Related]
18. The Relationship Between Tumor-Stroma Ratio, the Immune Microenvironment, and Survival in Patients With Spinal Chordoma.
Zou MX; Zheng BW; Liu FS; Wang XB; Hu JR; Huang W; Dai ZH; Zhang QS; Liu FB; Zhong H; Jiang Y; She XL; Li XB; Lv GH; Li J
Neurosurgery; 2019 Dec; 85(6):E1095-E1110. PubMed ID: 31501892
[TBL] [Abstract][Full Text] [Related]
19. Targeting myeloid suppressive cells revives cytotoxic anti-tumor responses in pancreatic cancer.
Sarhan D; Eisinger S; He F; Bergsland M; Pelicano C; Driescher C; Westberg K; Benitez II; Humoud R; Palano G; Li S; Carannante V; Muhr J; Önfelt B; Schlisio S; Ravetch JV; Heuchel R; Löhr MJ; Karlsson MCI
iScience; 2022 Nov; 25(11):105317. PubMed ID: 36310582
[TBL] [Abstract][Full Text] [Related]
20. Targeting Natural Killer Cells for Tumor Immunotherapy.
Zhang C; Hu Y; Shi C
Front Immunol; 2020; 11():60. PubMed ID: 32140153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]